13F Holdings
中文EN

ASND Ascendis Pharma A/S IFRS

Pharmaceutical Preparations · Nasdaq · SEC CIK 1612042 · Reporting currency EUR · Fiscal year ends 12/31

Financial factors as of 2025-12-31 (2025Q4), TTM = sum of the last four quarters

Growth

TTM revenue YoY98.0%
TTM net income YoY39.7%
TTM EPS YoY42.4%
Revenue 3-yr CAGR141.4%
Net income 3-yr CAGR—

Margins

Gross margin86.8%
Operating margin-18.9%
Net margin-31.7%
FCF margin—
EBITDA margin—

Returns

ROE—
ROA-18.4%
ROIC (approx.)-111.1%
Asset turnover0.58x

Leverage & solvency

Liabilities / assets112.5%
Debt / equity—
Current ratio1.04x
Interest coverage-1.69x

Cash quality & payout

Operating cash flow / net income-0.24x
Accruals ratio-22.7%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Unit: EUR FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue720.13M363.64M266.72M51.17M7.78M
Cost of revenue94.92M44.26M44.40M12.14M3.52M
Gross profit625.22M319.38M222.32M39.04M4.25M
R&D expense303.62M307.00M413.45M379.62M295.87M
SG&A expense457.87M291.14M264.41M221.23M160.18M
Operating income-136.27M-278.76M-455.54M-561.81M-451.79M
Interest expense80.65M65.50M44.06M30.68M3.91M
Pretax income-212.65M-373.24M-474.14M-577.82M-383.94M
Income tax15.38M4.84M7.30M5.38M-367,000
Net income-228.03M-378.08M-481.45M-583.19M-383.58M
EPS (basic)-3.76-6.53-8.55-10.40-7.00
EPS (diluted)-3.76-6.53-8.55-10.40-7.00
Balance sheet
Cash & equivalents616.04M559.54M392.16M444.77M446.27M
Receivables141.33M166.28M35.87M11.91M2.20M
Inventory301.53M295.61M208.93M130.67M75.41M
Current assets1.11B1.06B702.72M923.47M805.89M
PP&E, netmay include right-of-use assets (IFRS)146.48M98.71M110.63M129.09M126.05M
Total assets1.30B1.18B825.59M1.09B1.08B
Current liabilities1.07B907.86M736.51M171.27M100.36M
Short-term debt429.39M458.21M407.10M11.63M7.00M
Long-term debt385.25M365.08M223.00M387.56M97.97M
Total debt814.64M823.29M630.09M399.19M104.96M
Total liabilities1.47B1.29B971.28M826.39M201.29M
Shareholders' equity-162.82M-105.71M-145.70M263.35M883.63M
Net debt198.60M263.74M237.93M-45.58M-341.31M
Cash flow statement
Operating cash flow53.90M-306.20M-467.36M-495.70M-417.65M
Capital expenditure——2.44M14.49M23.70M
Free cash flow——-469.80M-510.19M-441.35M
Investing cash flow-8.48M6.88M286.47M61.73M-110.58M
Financing cash flow36.33M443.93M134.29M396.77M351.39M
Stock-based compensation116.17M95.51M66.66M64.18M66.83M
Share buybacks17.40M00105.31M21.61M

Free plan shows the latest 5 periods; Pro shows all 11 🔒

· This company reports under IFRS: some line items differ from US GAAP — operating income is not required, interest expense may be broader "finance costs", and banks have no standard revenue line.

· Amounts are in the company's reporting currency, EUR, not USD; the site does no currency conversion.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.